Drugs / NY-ESO-1 TCR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05620693 | Nov 2022 → Dec 2025 overdue | soft tissue sarcoma | Shenzhen University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 TCR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05620693 ↗ |
| Modality | Cell therapy | “NY-ESO-1 TCR-T cell” NCT05620693 ↗ |